Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Mechanism of Action

  • The therapeutic role of implanted vagus nerve stimulation is well established in several disorders related to autonomic dysfunction.1–4
  • In an animal model, excessive glutamate levels in the trigeminal nucleus caudalis (TNC) are believed to be a marker for increased trigeminal pain.5
  • In an animal model, non-invasive vagus nerve stimulation (nVNS) demonstrates the ability to suppress high glutamate levels in the TNC, which may be the mechanism by which it alleviates the symptoms of headache.5

gammaCore nVNS Mechanism of Action5

Mechanism+of+Action


Sources
1. Groves DA, Brown VJ. Vagal nerve stimulation: a review of its applications and potential mechanisms that mediate its clinical effects. Neurosci Biobehav Rev. 2005;29(3):493-500.
2. Krahl SE, Clark KB, Smith DC, Browning RA. Locus coeruleus lesions suppress the seizure- attenuating effects of vagus nerve stimulation. Epilepsia. 1998;39(7):709-714.
3. Berry SM, Broglio K, Bunker M, Jayewardene A, Olin B, Rush JA. A patient?level meta-analysis of studies evaluating vagus nerve stimulation therapy for treatment-resistant depression. Med Devices (Auckl). 2013; 6: 17-35.
4. Daban C, Martinez-Aran A, Cruz N, Vieta E. Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review. J Affect Disord. 2008;110(1-2):1-15.
5. Oshinsky ML, Murphy AL, Hekierski H Jr., Cooper M, Simon BJ. Non-invasive vagus nerve stimulation as treatment for trigeminal allodynia. Pain (2014), doi: http://dx.doi.org/10.1016/j.pain.2014.02.009.

gammaCore+logo